אנחנו בפייסבוק
Michael Ordman, a contributor for The Jerusalem Post highlights Israel's latest achievements in the fields of technology, health, and business has praise for Pluristem Therapeutics Inc. (NASDAQ: PSTI).
Citing the festival of Rosh Hashana as an opportunity to celebrate the creativity of the citizens of the Jewish State, Ordman points to Israeli researchers and bio-techs who continue to create new medical treatments that could give patients a new lease of life in the coming year.
"Pluristem's unique Placental eXpanded (PLX) stem cells continue to save people suffering from bone marrow failure," writes Ordman. "The latest was a 45-year-old man who had undergone chemotherapy and a bone-marrow transplant, due to leukemia. There were no side effects and the man has now been discharged from Hadassah medical centre in Jerusalem."
Shares of the Israeli bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders have been trading higher following a recent financing in anticiaption of US Food and Drug Administration approval for orphan drug status of the firm's PLacental eXpanded (PLX) cells to treat patients suffering from aplastic anemia.
With orphan drug status by the FDA the PLX cell therapy would gain multiple benefits including seven years of marketing exclusivity (from the day the candidate is cleared by the FDA) in the US for the indication.
Already Pluristem enjoys orphan drug status for using PLX cells to treat patients suffering from Buerger's disease since August 2011. The disease results in inflammation and clotting of blood vessels thereby reducing the flow of blood in these areas.
הודעות חשובות
שימו לב: שחקני המעוף החלו בסגירת פוזיציות יוני ומעבר ליולי !
13:18 ; 2900.25
שחקן מעוף 25.06.2025, 13:18צהרים טובים.
כפי שציינו במהלך החודש ואף בסקירה האחרונה, ביוני שחקני המעוף לא היו נוכחים כלל. 35% בלבד מסך
הכתיבות המשויך לנו, בחודש שהיה לנו ברור שהולך להיות תנודתי להחריד. ...